FY2024 EPS Estimates for CeriBell Lowered by William Blair

CeriBell (NASDAQ:CBLL) – Equities research analysts at William Blair lowered their FY2024 earnings per share estimates for CeriBell in a research note issued to investors on Wednesday, November 13th. William Blair analyst M. Andrew now anticipates that the company will earn ($3.07) per share for the year, down from their prior forecast of ($0.99). William Blair currently has a “Outperform” rating on the stock. The consensus estimate for CeriBell’s current full-year earnings is ($2.11) per share. William Blair also issued estimates for CeriBell’s Q4 2024 earnings at ($0.34) EPS, Q1 2025 earnings at ($0.30) EPS, Q2 2025 earnings at ($0.30) EPS, Q3 2025 earnings at ($0.28) EPS, Q4 2025 earnings at ($0.29) EPS, FY2025 earnings at ($1.17) EPS and FY2026 earnings at ($1.01) EPS.

CeriBell (NASDAQ:CBLL) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($1.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($1.03). The company had revenue of $17.20 million during the quarter, compared to analysts’ expectations of $17.06 million.

Several other research firms have also weighed in on CBLL. JPMorgan Chase & Co. began coverage on shares of CeriBell in a research note on Tuesday, November 5th. They issued an “overweight” rating and a $32.00 price objective on the stock. Bank of America initiated coverage on shares of CeriBell in a research note on Tuesday, November 5th. They issued a “buy” rating and a $32.00 price target on the stock. TD Cowen assumed coverage on CeriBell in a research report on Tuesday, November 5th. They set a “buy” rating and a $31.00 price objective for the company. Canaccord Genuity Group upped their target price on CeriBell from $30.00 to $31.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. Finally, Canaccord Genuity Group started coverage on CeriBell in a report on Tuesday, November 5th. They set a “buy” rating and a $30.00 price target for the company. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $31.20.

CeriBell Price Performance

NASDAQ CBLL opened at $25.00 on Monday. CeriBell has a 52-week low of $23.00 and a 52-week high of $29.53.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.